UBS Raises Monte Rosa Therapeutics Price Target to $19 per Share
UBS initiated coverage of Monte Rosa Therapeutics with a Buy rating and lifted its price target to $19 from $17 per share.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Dow Jones Newswires, citing analyst-action data from Benzinga, reported that UBS assumed coverage of Monte Rosa Therapeutics with a Buy rating.
UBS also raised its target for the company’s shares to $19 per share from $17 previously. The rating action was published on October 12, 2026, at 13:47 GMT.
why it matters
The update marks a change in UBS’s assessment of Monte Rosa Therapeutics and may draw market attention to the company’s shares and available analyst coverage.
instruments
sources
- Monte Rosa Therapeutics Price Target Raised to $19.00/Share From $17.00 by UBS — Dow Jones Newswires, 12 October 2026 at 13:47 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗